haloperidol and moclobemide

haloperidol has been researched along with moclobemide in 13 studies

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19901 (7.69)18.7374
1990's1 (7.69)18.2507
2000's5 (38.46)29.6817
2010's6 (46.15)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Lombardo, F; Obach, RS; Waters, NJ1
Bleich, S; Kornhuber, J; Rupprecht, R; Terfloth, L; Wiltfang, J1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Sen, S; Sinha, N1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL1
Bizière, K; Kan, JP; Roncucci, R; Wermuth, CG; Worms, P1
König, F; Löble, M; Wolfersdorf, M1
Kurasawa, M; Nakamura, K1
Antonello Rubin, M; da Cunha, C; da Silva Sant'Anna, G; de Almeida Cabrini, D; de Vargas Pinheiro, F; Dombrowski, PA; Fachinetto, R; Ferreira, J; Gauze Bonacorso, H; Machado, P; Pinto Martins, MA; Villarinho, JG; Zanatta, N1

Other Studies

13 other study(ies) available for haloperidol and moclobemide

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:6

    Topics: Binding Sites; Computer Simulation; Databases, Factual; Models, Chemical; Models, Molecular; Molecular Structure; Molecular Weight; Psychotropic Drugs; Serotonin 5-HT3 Receptor Antagonists; Structure-Activity Relationship

2009
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:2

    Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship

2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
    PloS one, 2016, Volume: 11, Issue:10

    Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat

2016
SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents.
    The Journal of pharmacology and experimental therapeutics, 1987, Volume: 240, Issue:1

    Topics: 5-Hydroxytryptophan; Amphetamines; Animals; Antidepressive Agents; Behavior, Animal; Benzamides; Body Temperature; Catalepsy; Clorgyline; Drug Interactions; Female; Haloperidol; Imipramine; Levodopa; Male; Mice; Moclobemide; Monoamine Oxidase Inhibitors; Motor Activity; Nomifensine; Oxotremorine; Pargyline; Piperidines; Pyridazines; Rats; Rats, Inbred Strains; Reserpine; Selegiline; Stereotyped Behavior

1987
[Depressive stupor--malignant neuroleptic syndrome--serotonin syndrome. A case contribution to a difficult differential diagnosis].
    Der Nervenarzt, 1996, Volume: 67, Issue:5

    Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzamides; Depressive Disorder; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Haloperidol; Humans; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Neuroleptic Malignant Syndrome; Neurologic Examination; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Syndrome; Trimipramine

1996
Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.
    European journal of pharmacology, 2001, May-18, Volume: 420, Issue:1

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Bromocriptine; Diazepam; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Fear; Fluvoxamine; Haloperidol; Indophenol; Male; Maze Learning; Mecamylamine; Mice; Mice, Inbred ICR; Moclobemide; Motor Activity; Nicotine; Nicotinic Antagonists; Nortriptyline; Physostigmine; Picolinic Acids; Pyrrolidinones; Serotonin Antagonists; Serotonin Receptor Agonists; Social Behavior; Stress, Psychological

2001
Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice.
    Progress in neuro-psychopharmacology & biological psychiatry, 2012, Oct-01, Volume: 39, Issue:1

    Topics: Animals; Anisoles; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Brain; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Imidazolines; Isoenzymes; Kinetics; Male; Methysergide; Mice; Moclobemide; Monoamine Oxidase Inhibitors; Piperazines; Pyridines

2012